Andrea Valle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Valle has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alessia Mercalli
San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
1 shared publication- Antonio Citro
San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
1 shared publication Daniela Liberati
San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
1 shared publication- Elisa Cantarelli
San Raffaele Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
1 shared publication - Lorenzo Piemonti
Diabetes Research Institute (DRI), IRCCS Ospedale San Raffaele, Italy
1 shared publication Luisa Daffonchio
Research and Development Department, Dompè Farmaceutici S.p.A, L'Aquila, Italy
1 shared publication
Latest Publications
- Open Access
- 14 October 2014
- Published by American Diabetes Association in Diabetes
- Vol. 64 (4) , 1329-1340
CXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice
Chemokines and their receptors have been associated with or implicated in the pathogenesis of type 1 diabetes (T1D), but the identification of a single specific chemokine/receptor pathway that may constitute a suitable target for the development of therapeutic interventions is still lacking. Here, we used the multiple low doses (MLD)-streptozotocin (STZ) injection and the NOD mouse models to investigate the potency of CXCR1/2 inhibition to prevent inflammatory- and autoimmunity-mediated damage of pancreatic islets. Reparixin and ladarixin, non-competitive allosteric inhibitors, were used to obtain the pharmacologic blockade of CXCR1/2. Transient blockade of said receptors was effective in preventing inflammatory-mediated damage in MLD-STZ and in preventing and reverting diabetes in NOD mice. Blockade of CXCR1/2 was associated with insulitis inhibition and modification of leucocytes distribution in blood, spleen, bone marrow and lymph nodes. Among leucocytes, CXCR2+ myeloid cells were the most decreased subpopulations. All together these results propose CXCR1/2 chemokine receptors as “master regulators” of diabetes pathogenesis. The demonstration that this strategy may be successful in preserving the residual β-cells holds the potential to make a significant change in the approach to management of human T1D.
- 14 October 2014
- Published by American Diabetes Association in Diabetes
- Vol. 64 (4) , 1329-1340
Open AccessCXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice
Chemokines and their receptors have been associated with or implicated in the pathogenesis of type 1 diabetes (T1D), but the identification of a single specific chemokine/receptor pathway that may constitute a suitable target for the development of therapeutic interventions is still lacking. Here, we used the multiple low doses (MLD)-streptozotocin (STZ) injection and the NOD mouse models to investigate the potency of CXCR1/2 inhibition to prevent inflammatory- and autoimmunity-mediated damage of pancreatic islets. Reparixin and ladarixin, non-competitive allosteric inhibitors, were used to obtain the pharmacologic blockade of CXCR1/2. Transient blockade of said receptors was effective in preventing inflammatory-mediated damage in MLD-STZ and in preventing and reverting diabetes in NOD mice. Blockade of CXCR1/2 was associated with insulitis inhibition and modification of leucocytes distribution in blood, spleen, bone marrow and lymph nodes. Among leucocytes, CXCR2+ myeloid cells were the most decreased subpopulations. All together these results propose CXCR1/2 chemokine receptors as “master regulators” of diabetes pathogenesis. The demonstration that this strategy may be successful in preserving the residual β-cells holds the potential to make a significant change in the approach to management of human T1D.